CNS Pharmaceuticals, Inc.

2100 West Loop South, Suite 900

Houston, TX 77027


February 1, 2021




U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549


Re:CNS Pharmaceuticals, Inc.
  Registration Statement on Form S-3
  File No. 333-252471


Ladies and Gentlemen:


Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on February 3, 2021, or as soon thereafter as possible on such date.


  Very truly yours,
  CNS Pharmaceuticals, Inc.
  By: /s/ Christopher Downs                     
  Name: Christopher Downs
  Title: Chief Financial Officer